Skip to main content
SpringerLink
Log in

Maintenance Therapy in Gastro-oesophageal Reflux Disease

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Gastro-oesophageal reflux disease (GORD) is a chronic condition. Symptom control and the maintenance of healing of erosive oesophagitis, if present, are important topics.

In patients responding to a proton pump inhibitor (PPI) and showing no treatment symptoms it is appropriate to consider long-term treatment strategies, whether continuous, intermittent or on demand. Maintenance PPI therapy is well tolerated for up to 10 years of continuous use. Furthermore, tachyphylaxis does not occur during long-term maintenance PPI therapy. Previous concerns about risks of long-term PPI therapy in Heliobacter pylorinegative or H. pyloripositive patients have not materialized, while no cases of intestinal metaplasia with dysplasia or adenocarcinoma were found.

The choice between medical and surgical therapy should depend upon informed patient preference. The optimal candidate for antireflux surgery is a young patient, with typical GORD symptoms, with erosive oesophagitis, with previous complete symptom resolution on acid-suppression therapy and unable to undergo continuous therapy, or alternatively in patients with regurgitation predominating over heartburn as long as the surgical procedures are conducted by an expert surgical team.

Endoscopic therapy for erosive GORD should currently be regarded as experimental. The endoscopic procedures are safe, although they remain untested in patients with severe erosive oesophagitis and/or significant hiatal hernia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2
Table II

Similar content being viewed by others

References

  1. Eissele R, Arnold R. Long-term management of GERD. In: Misiewicz JJ, editor. Management Issues in Gastroeso-phageal Reflux Disease. London: Life Science Communications, 1999: 24–33

    Google Scholar 

  2. Richter JE. Gastroesophageal reflux disease. In: Yamada T, editor. Textbook of Gastroenterology 4th ed. Philadelphia: Lippincott, Williams and Wilkins, 2003:1196–224

    Google Scholar 

  3. Bixquert M. Lo primero es conocer la historia natural. In: Dominguez JE, Sobrino M, editors. Enfermedad por reflujo gastroesofágico. Pautas diagnóstico-terapéuticas para la práctica clínica. Barcelona: Prous Science, 2003: 1–10

    Google Scholar 

  4. Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management — The Genval Workshop Report. Gut 1999; 44 Suppl 2: S1–S16

    Article  Google Scholar 

  5. Dent J, Jones R, Kahrilas P, et al. Management of gastro-oesophageal reflux disease in general practice. BMJ 2001; 322: 344–7

    Article  PubMed  CAS  Google Scholar 

  6. Galmiche JP, Bruley des Varannes S. Endoscopy-negative reflux disease. Curr Gastroenterol Rep 2001; 3: 206–14

    Article  PubMed  CAS  Google Scholar 

  7. Pace F, Bollani S, Molteni P, et al. Natural history of gastro-esophageal reflux disease without esophagitis (NERD) — a reappraisal 10 years on. Dig Liver Dis 2004; 36: 111–5

    Article  PubMed  CAS  Google Scholar 

  8. Kahrilas PJ, Pandolfino JE. Gastroesophageal reflux disease and its complications, including Barrett’s metaplasia. In: Sleisenger & Fordtran’s Gastrointestinal and Liver Disease. 7th ed. Philadelphia: Saunders, 2002: 599–622.

    Google Scholar 

  9. Malfertheiner P, Megraud F, O’Morain C, et al. Current concepts in the management of H. pylori infection — The Maastricht 2-2000 consensus report. Aliment Pharmacol Ther 2002; 16: 167–80

    Article  PubMed  CAS  Google Scholar 

  10. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and H. pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334: 1018–22

    PubMed  CAS  Google Scholar 

  11. Freston JW. Should we eradicate H. pylori before long term antireflux therapy? Gut 2001; 49: 616–7

    CAS  Google Scholar 

  12. Lundell L, Miettinen P, Myrvold HE, et al. Lack of effect of acid suppression therapy on gastric atrophy. Gastroenterology 1999; 117: 319–26

    Article  PubMed  CAS  Google Scholar 

  13. McColl KEL. H. pylori infection and long term proton pump inhibitor therapy. Gut 2004; 53: 5–7

    CAS  Google Scholar 

  14. Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, et al. Cure of H. pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut 2004; 53: 12–20

    CAS  Google Scholar 

  15. Freston JW. Long-term acid control and proton pump inhibitors: interactions and safety issues in perspective. Am J Gastroenterol 1997; 92 Suppl 5: 1S–7S

    Google Scholar 

  16. Armstrong D, Marshall JK, Chiba N, et al. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults-update 2004. Can J Gastroenterol 2005; 19: 15–35

    PubMed  Google Scholar 

  17. Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety and influence on gastric mucosa. Gastroenterology 2000; 118: 661–4

    Article  PubMed  CAS  Google Scholar 

  18. Ramakrishnan A, Katz PO. Pharmacologic management of gastroesophageal reflux disease. Curr Gastroenterol Rep 2002; 4: 218–24

    Article  PubMed  Google Scholar 

  19. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 172–80

    Article  PubMed  CAS  Google Scholar 

  20. Marzo M, Alonso P, Bonfill X, et al. Centro Cochrane Iberomaericano. Clinical practice guideline on the management of patients with gastroesophageal reflux disease (GERD). Gastroenterol Hepatol 2002; 25: 85–110

    PubMed  CAS  Google Scholar 

  21. Lauritsen K, Deviere J, Bigard MA, et al. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux esophagitis: Metropole study results. Aliment Pharmacol Ther 2003; 17: 333–41

    Article  PubMed  CAS  Google Scholar 

  22. Bardhan KD, Muller-Lissner S, Bigard MA, et al. Symptomatic gastro-esophageal reflux disease: double-blind controlled study of intermittent treatment with omeprazole or ranitidine. Br Med J 1999; 318: 502–7

    Article  CAS  Google Scholar 

  23. Stalhammar N-O, Carlsson J, Peacock R, et al. Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-esophageal reflux disease. Pharmacoeconomics 1999; 16: 483–7

    Article  PubMed  CAS  Google Scholar 

  24. Wiklund I, Bardhan KD, Müller-Lissner S, et al. Quality of life during acute and intermittent treatment of gastroesophageal reflux disease with omeprazole compared with ranitidine. Results from a multi-center clinical trial. Ital J Gastroenterol Hepatol 1998; 30: 19–27

    CAS  Google Scholar 

  25. Richter JE. Gastroesophageal reflux disease in the older patient: presentation, treatment and complications. Am J Gastronterol 2000; 95: 368–72

    CAS  Google Scholar 

  26. Lind T, Havelund T, Lundell L, et al. On-demand therapy with omeprazole for the long-term management of patients with heartburn without esophagitis — a placebo-controlled randomized trial. Aliment Pharmacol Ther 1999; 13: 907–14

    Article  PubMed  CAS  Google Scholar 

  27. Talley NJ, Venables TL, Green JRB, et al. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastroesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months. Eur J Gastroenterol Hepatol 2002; 14: 857–63

    Article  PubMed  CAS  Google Scholar 

  28. Ponce J, Argüello L, Bastida G, Ponce M, Ortiz V, Garrigues V. On-demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health-related quality of life, and patient satisfaction. Dig Dis Sci 2004; 49: 931–6

    Article  PubMed  CAS  Google Scholar 

  29. Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease. JAMA 2001; 285: 2331–8

    Article  PubMed  CAS  Google Scholar 

  30. Peterson WL, Kharilas PJ, Berardi RR, et al. Improving the management of GERD: evidence-based therapeutic strategies, in Freston JW (ed), Acid Related Diseases Am Gastroenterol Assoc, Self Study Program 2003; 15–40

  31. Carballo F. Tratamiento a largo plazo de la ERGE. Análisis coste-efectividad del tratamiento farmacológico (a demanda y continuo) y el tratamiento quirúrgico. Gastro-enterol Hepatol 2001; 24 Suppl 2: 54–60

    Google Scholar 

  32. Bammer T, Hinder RA, Klaus A, et al. Five-to-eight year outcome of the first laparoscopic Nissen fundoplications. J Gastrointestinal Surg 2001; 5: 43–8

    Article  Google Scholar 

  33. Nilsson G, Wenner J, Larsson S, Jonson F. Randomized clinical trial of laparoscopic versus open fundoplication for gastro-esophageal reflux. Br J Surg 2004; 91: 552–9

    Article  PubMed  CAS  Google Scholar 

  34. Johnson DA. Endoscopic therapy for GERD-baking, sewing or stuffing: an evidence-based perspective. Rev Gastroenterol Disord 2003; 3: 142–9

    PubMed  Google Scholar 

  35. Hogan WJ. Endoscopic therapy for gastroesophageal reflux disease. Curr Gastroenterol Rep 2003; 5: 206–12

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Valencia, and Digestive Diseases Service, ‘Arnau de Vilanova’ Hospital, Valencia, Spain

    Miguel Bixquert Jiménez

Authors
  1. Miguel Bixquert Jiménez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Miguel Bixquert Jiménez.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jiménez, M.B. Maintenance Therapy in Gastro-oesophageal Reflux Disease. Drugs 65 (Suppl 1), 59–66 (2005). https://doi.org/10.2165/00003495-200565001-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200565001-00009

Keywords

Search

Navigation